Omega-3 API Pharma Grade is released under the grade codes O3-API-EE70, O3-API-EE85, O3-API-EE97, O3-API-TG60, and O3-API-TG70. The numeric suffix denotes the minimum combined eicosapentaenoic acid and docosahexaenoic acid content determined by GC-FID after derivatisation. Ethyl ester grades are manufactured by ethylation of refined marine oil, short-path molecular distillation, winterisation, and deodorisation. Re-esterified triglyceride grades are produced by glycerol-backbone re-esterification after concentration. Both molecular forms are supplied as water-immiscible oily liquids with compendial release documentation for tablet, hard-capsule, soft-gelatin capsule, granule, oral liquid, and parenteral applications. Injectable-grade designations carry the suffix P, as in O3-API-EE85P or O3-API-EE97P, and are subjected to additional bioburden, endotoxin, particulate, and oxidative-stability controls.

The API is specified for direct compression, wet granulation, softgel encapsulation, and aseptic lipid-emulsion processing. At temperatures below −5°C to −10°C the material can solidify or become turbid; controlled warming to 20–25°C under nitrogen restores clarity. Storage is in amber glass or 316L stainless steel vessels with nitrogen overlay and headspace oxygen ≤2.0% v/v. The material should not be exposed to ambient air for more than 2 h during open handling. Repeated partial-container use should be blanketed with nitrogen after each opening.

The higher-concentration grade O3-API-EE97 is intended for high-potency prescription capsules where a 1 g dose requires minimal excipient load. The 97% combined EPA+DHA grade reduces capsule oil fill volume by approximately 27% relative to a 70% grade for equivalent dose. However, the higher concentration also increases the mole fraction of polyunsaturated fatty acids and lowers the activation energy for oxygen addition; the peroxide value and anisidine value kinetics are therefore more sensitive to residual oxygen and iron contamination. At headspace oxygen above 2% v/v, the 97% grade shows faster TOTOX increase than the 70% grade when no antioxidant is present. Release-documentation measurements under accelerated conditions at 40°C without antioxidant typically show peroxide value increase of 0.8–1.2 meq/kg/month for EE70 and 1.2–2.0 meq/kg/month for EE97 at headspace oxygen 5% v/v. With d-α-tocopherol at 0.3% w/w and ascorbyl palmitate at 0.1% w/w, the increase is reduced to 0.1–0.3 meq/kg/month. These values are release-documentation measurements and do not replace finished-product stability protocols.

What process limits apply to oral solid dosage forms and granulation?

In direct compression, the liquid API is adsorbed onto porous carriers before blending. Unadsorbed oil fractions above 3–5% w/w produce sticking and ejection-force drift on rotary presses at 15–25 kN compaction force. Fumed silica, calcium silicate, or porous starch are used at oil-to-carrier mass ratios of 1:1 to 1:2. The resulting powder blend is mixed with microcrystalline cellulose, anhydrous dibasic calcium phosphate, croscarmellose sodium, and magnesium stearate. Lubrication is limited to 0.5–1.0% w/w and blend time 3–5 min to avoid lipid filming on the carrier. The blend is compressed to tablet hardness 80–140 N and friability ≤1.0% w/w using 10–25 kN compaction force.

For hard capsules, the adsorbed oil is milled to particle size <250 μm and filled into low-moisture HPMC shells. Tamping-pin capsule fill machines operate with dosing chamber bulk density between 0.45–0.65 g/cm³. Fill weight variation must meet Ph. Eur. 2.9.5 for single-dose preparations. Capsule shell selection with low moisture HPMC is preferred because lipid migration can embrittle conventional gelatin shells.

Wet granulation with aqueous binders is generally avoided because water can promote hydrolysis and increase free fatty acids. Non-aqueous granulation with absolute ethanol and polyvinylpyrrolidone can be used if drying product temperature remains ≤35°C and residual solvent is reduced to ≤0.5% w/w. Granulation in a high-shear mixer with impeller tip speed <10 m/s and jacket coolant at 5–15°C is used with nitrogen-blanketed process air. Antioxidant loading with d-α-tocopherol 0.2–0.5% w/w and ascorbyl palmitate 0.05–0.2% w/w is added during oil handling. Metal contact with copper, brass, or unlined carbon steel is not permitted; 316L stainless steel or glass-lined surfaces are standard.

For granule production, a fluid-bed unit with top-spray nozzle, inlet air temperature 25–35°C, dew point −25°C, and atomising pressure 1.5–2.5 bar is used. Spray rate for a 1 kg batch is typically 15–25 g/min. Higher spray rates create overwetting of the oily carrier and agglomeration that reduces granule friability below 1.0% w/w. Granules are dried to loss on drying ≤2.0% w/w and milled through a 0.8 mm screen. The granules can be filled into sachets or capsules or compressed into tablets with a hydrophobic lubricant system.

Endotoxin, particulate matter, and injectable lipid-phase handling

Injectable-grade material is released with low bioburden, endotoxin ≤0.25 EU/mg per Ph. Eur. 2.6.14, and particulate matter limits per Ph. Eur. 2.9.19. The oil is filtered through 0.22 μm membranes in a closed system after pre-filtration through 1.0 μm to reduce membrane clogging. Filter pressure differential is maintained below 0.8 bar. Bioburden and sterility testing are performed according to Ph. Eur. 2.6.1 and Ph. Eur. 2.6.2. Residual moisture is controlled below 0.1% w/w because water accelerates hydrolysis and supports microbial growth in non-sterile storage conditions.

For intravenous lipid emulsions, the oil is combined with egg phospholipid and glycerin at 60–75°C, then homogenised at 500–1200 bar in a microfluidizer or high-pressure homogenizer. Mean droplet diameter after terminal sterilization is 200–500 nm. The percentage of fat globules above 5 μm is limited by the finished emulsion monograph. Terminal sterilization at 121°C for 15 min can increase peroxide value by 0.5–1.5 meq O₂/kg; therefore, dissolved oxygen is kept at ≤1.0 mg/L and headspace oxygen ≤1% v/v. The use of silicone tubing is recommended for transfer lines; PVC is avoided because the oil can extract plasticizer.

For oil-based intramuscular injection, formulation may require benzyl alcohol or benzyl benzoate as co-solvent. Compatibility and peroxide values should be re-tested after terminal sterilisation. Published data for neat omega-3 oil injection at concentration above 100 mg/mL without co-solvent or emulsifier is limited; formulation-specific sterilisation and stability data are required. Injectable-grade material should not be assumed to be equivalent to oral-grade material simply by filtration; endotoxin control, particulate load, and sterilisation-induced oxidation must be verified.

Conventional food-grade fish oil 18/12 contains approximately 30% combined EPA+DHA, with cholesterol levels often above 0.5% and oxidation marker values that are not controlled to compendial monograph limits. The concentrated omega-3 API reduces the total oil dose required to deliver a 1000 mg omega-3 acid ethyl ester capsule, and residual triglycerides, saturated fats, and marine odour compounds are removed by molecular distillation. Krill oil and algal oils differ in polar lipid class and EPA:DHA ratio. Krill oil presents EPA and DHA bound to phospholipids, which can affect emulsification and digestive lipolysis, but the EPA+DHA content is typically less than 40%. Algal DHA oil may contain <1% EPA and therefore fails the combined assay specification for omega-3 acid ethyl esters 90 unless blended with fish-derived EPA concentrates. Cod liver oil contains variable vitamin A palmitate and vitamin D3, which introduces additional stability and safety controls not required for concentrated omega-3 API. The API is released under ICH Q7 GMP for active substances and documented in a drug master file.

When re-esterified triglyceride forms replace ethyl esters in softgel shell compatibility testing

Ethyl ester grades are less viscous and more polar than re-esterified triglyceride forms. The lower viscosity improves capsule fill accuracy at 25–35°C, but ethyl ester migration into shell gelatin can increase shell softening and may require lower fill moisture or additional glycerin adjustment. Re-esterified triglyceride grades show lower shell migration and are preferred when fill weights 800–1000 mg are required or when shells exhibit crosslinking during long-term storage at 40°C/75% RH. Softgel fill pumps are set with fill weight tolerance ±3% and needle temperature 30–40°C for ethyl ester grades. Triglyceride grades may require fill temperature 35–45°C to maintain flow through the injection wedge.

Shell compatibility is assessed by storing filled softgel units at 40°C/75% RH for 6 months in HDPE bottles with induction seals. Shell hardness, seal thickness, and rupture force are measured with a texture analyser. Gelatin shell moisture is targeted at 8–10% w/w; lower moisture increases brittleness, and higher moisture increases deformation. The test matrix should include non-enteric and enteric shell formulations because methacrylic acid copolymer layers can alter water-vapour transmission and affect shell plasticizer migration.

Enteric coating of omega-3 softgels is applied when gastric eructation or taste masking is required. A methacrylic acid copolymer dispersion is applied to a weight gain of 6–10% w/w in a perforated pan coater with inlet air temperature 30–40°C and product temperature 22–28°C. The API is not contacted by the aqueous coating solution; the coating is applied to the gelatin shell only. After coating, the softgels are dried at 22–25°C and 40–50% relative humidity until shell moisture returns to 8–10% w/w.

For granules intended for compression or capsule filling, lipid adsorption onto microcrystalline cellulose or silicified carriers followed by extrusion-spheronization yields pellets with diameter 0.8–1.2 mm and friability <1.0% w/w. The extrusion die temperature is kept below 30°C to avoid oil exudation and paste formation. The pellets can be coated with a moisture-protective polymer if the final sachet or capsule requires humidity exposure above 60% relative humidity. Storage of granules in unlined paper-lined cartons is not recommended because oxygen permeability accelerates peroxide formation.

The API should not be exposed to strong acids, strong bases, or lipolytic enzymes during formulation. Ethyl ester hydrolysis or triglyceride lipolysis changes the EPA:DHA distribution and increases free fatty acid level. Contact with transition-metal ions, especially copper and iron, accelerates lipid peroxidation and should be controlled by using chelating excipients such as citric acid monohydrate at 0.05–0.2% w/w in aqueous emulsion formulations. Storage at 15–25°C in closed, amber containers retains peroxide value below monograph limit for 24 months in the manufacturer’s stability protocol under nitrogen.